BSE filing, NSE: GLAND. Summary written from the filing by ALFA Finder's alert engine.
Gland Pharma Ltd: key numbers
- Share price
- ₹3,169.60
- Market cap
- ₹52,302 Cr
- Revenue (annual)
- ₹6,431 Cr
- Net profit (annual)
- ₹1,027 Cr
- P/E (TTM)
- 46.3×Sector 42.0×
- Promoter holding
- 45.75%-6.02% QoQ
- FII holding
- 10.36%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Gland Pharma Ltd
All →Gland Pharma Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹18,336 Mn (+23% YoY), PAT ₹2,908 Mn (+58%), adj. EBITDA margin 27%. US CDMO and launches lead; India and RoW weak.
Gland Pharma Q2 FY27 Results: Net Profit ₹290.8 Cr, Up 58.3% YoY
Gland Pharma Ltd reported revenue from operations of ₹1,834 Cr (+23.3% YoY) and net profit of ₹290.8 Cr (+58.3% YoY) for Q2 FY27.
- Key figure
- Net profit ₹290.8 Cr · +58.3% YoY
Gland Pharma Regulatory Approval
Gland Pharma received USFDA approval for Methylprednisolone Acetate Injectable Suspension USP in multiple vial formats. The product is bioequivalent to Pfizer's Depo-Medrol in a ~$214M US market.
Gland Pharma Management Change
Gland Pharma appointed Ajay Sahni as CEO of its wholly-owned subsidiary Gland Pharma International Pte. Ltd, effective 2 November 2026. He will lead the Cenexi business.
Gland Pharma Business Update
Gland Pharma reports that USFDA concluded an unannounced cGMP inspection at its Dundigal formulation facility with four procedural Form 483 observations. No monetary impact is stated, and corrective actions will be submitted within the stipulated period.
Gland Pharma Board Meeting Date
Gland Pharma Ltd scheduled a board meeting for November 06, 2026, to approve the unaudited standalone and consolidated financial results for the quarter ending September 30, 2026.
Other results update announcements
All →Cohance Lifesciences Results Update
Cohance Lifesciences issued a press release on its unaudited Q2 and H1 FY27 results. It reported lower year-on-year revenue and an expected stronger second half.
Amir Chand Jagdish Kumar (Exports) Results Update
H1 FY27 revenue rose 32.9% to Rs 1,358 crore; PAT rose 59.7% to Rs 78 crore. A new Saudi subsidiary was also incorporated.
Globe Enterprises (India) Results Update
Globe Enterprises reported Q2 FY27 total revenue of ₹21,028.35 Lakhs, up 32.62% YoY, with EBITDA up 24.50%. H1 FY27 revenue rose 28.70% in a press release accompanying its results.
Kaka Industries Results Update
Kaka Industries reported H1 FY27 revenue up 26.1% and PAT up 32.9%. The release also notes a 7.5 MW captive solar plant commissioned in July 2026.
- solar capacity
- 7.5 MW
Coromandel International Results Update
Q2 FY27 standalone PAT fell 33% to Rs 548 Crore as EBITDA declined 21%. Fertiliser margins were squeezed by raw material costs.
Pritika Auto Industries Results Update
Pritika Auto reported Q2 FY27 revenue of Rs.153.19 Crore, up 31.55% YoY, and PAT of Rs.7.43 Crore. The media release also flags a European export order won by its subsidiary.